力生制药
(002393)
| 流通市值：45.18亿 | | | 总市值：46.50亿 |
| 流通股本：3.00亿 | | | 总股本：3.09亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 332,282,846.72 | 1,392,014,298.29 | 1,007,280,440.26 | 731,508,082.68 |
| 营业收入 | 332,282,846.72 | 1,392,014,298.29 | 1,007,280,440.26 | 731,508,082.68 |
| 二、营业总成本 | 275,933,687.7 | 1,237,397,826.21 | 871,042,976.72 | 619,756,337.76 |
| 营业成本 | 148,480,217.84 | 622,787,319.63 | 424,869,882.93 | 298,776,639.49 |
| 税金及附加 | 5,442,807.77 | 23,741,412.15 | 16,807,326.2 | 11,661,266.8 |
| 销售费用 | 77,812,332.46 | 374,553,639.51 | 280,142,605.86 | 222,721,274.04 |
| 管理费用 | 30,559,500.45 | 149,763,102.5 | 105,314,299.64 | 71,443,554.93 |
| 研发费用 | 19,977,674.28 | 115,192,280.36 | 90,304,744.13 | 59,994,195.46 |
| 财务费用 | -6,338,845.1 | -48,639,927.94 | -46,395,882.04 | -44,840,592.96 |
| 其中:利息费用 | 456,052.01 | 2,253,830.01 | 1,911,285.95 | 1,284,520.32 |
| 其中:利息收入 | 6,801,948.25 | 51,522,258.82 | 49,091,990.84 | 46,668,889.71 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 1,353,392.89 | 2,105,592.51 | 2,398,652.06 | -197,794.77 |
| 加:投资收益 | 3,306,226.21 | 324,770,617.56 | 319,543,582.3 | 315,674,594.19 |
| 资产处置收益 | - | 249,613.79 | 282,628.85 | 364,701.72 |
| 资产减值损失(新) | - | -20,080,500.19 | -16,435,037.58 | -16,435,037.58 |
| 信用减值损失(新) | 7,251.56 | 868,226.05 | 294,758.51 | 147,719.56 |
| 其他收益 | 1,361,839.04 | 6,600,782.15 | 3,679,718.55 | 2,678,401.67 |
| 四、营业利润 | 62,377,868.72 | 469,130,803.95 | 446,001,766.23 | 413,984,329.71 |
| 加:营业外收入 | 90,000.6 | 1,721,251.6 | 1,553,215.35 | 1,360,543.46 |
| 减:营业外支出 | 158,997.48 | 15,246,903.8 | 14,540,196.6 | 13,896,739.16 |
| 五、利润总额 | 62,308,871.84 | 455,605,151.75 | 433,014,784.98 | 401,448,134.01 |
| 减:所得税费用 | 9,243,309.67 | 32,878,707.12 | 58,729,889.06 | 56,110,667.64 |
| 六、净利润 | 53,065,562.17 | 422,726,444.63 | 374,284,895.92 | 345,337,466.37 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 53,065,562.17 | 422,726,444.63 | 374,284,895.92 | 345,337,466.37 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 51,882,970.53 | 416,283,339.38 | 370,740,371.53 | 342,923,994.39 |
| 少数股东损益 | 1,182,591.64 | 6,443,105.25 | 3,544,524.39 | 2,413,471.98 |
| 扣除非经常损益后的净利润 | 46,869,507.4 | 168,529,342.94 | 126,730,212.35 | 104,230,120.39 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.2 | 1.62 | 1.44 | 1.33 |
| (二)稀释每股收益 | 0.2 | 1.62 | 1.44 | 1.33 |
| 八、其他综合收益 | 2,438,356.16 | -412,435,477.98 | - | - |
| 归属于母公司股东的其他综合收益 | 2,438,356.16 | -412,435,477.98 | - | - |
| 九、综合收益总额 | 55,503,918.33 | 10,290,966.65 | 374,284,895.92 | 345,337,466.37 |
| 归属于母公司股东的综合收益总额 | 54,321,326.69 | 3,847,861.4 | 374,284,895.92 | 342,923,994.39 |
| 归属于少数股东的综合收益总额 | 1,182,591.64 | 6,443,105.25 | - | 2,413,471.98 |
| 公告日期 | 2026-04-24 | 2026-03-25 | 2025-10-24 | 2025-08-22 |
| 审计意见(境内) | | 标准无保留意见 | | |